Xu Yue-Hua, Zhang Guang-Bo, Wang Jia-Min, Hu Hua-Cheng
Department of Respiratory Medicine, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Saudi Med J. 2010 Sep;31(9):980-6.
To detect the expression of B7-H3 and CD133 in human non-small cell lung cancer (NSCLC) specimens and lung benign lesions, and to evaluate the correlation between the 2 biomarkers and clinicopathologic features.
This is a case-control study of 102 tissue specimens collected from NSCLC participants undergoing thoracic surgery in the Second Affiliated Hospital of Soochow University, Suzhou, China, between January 2006 and December 2008. From the 102 patients, 25 adjacent non-cancer samples were verified pathologically as normal tissue (positive group), and 24 benign inflammatory lesion tissues were used as control (negative group). Specimens from 126 participants were stained immunohistochemically using Image-Pro Plus software, and the cell number was measured in each section.
Of the 102 specimens, 71 expressed B7-H3, and 51 expressed CD133, higher than that in benign lesions (p<0.001) or non-cancer tissues (p<0.001). B7-H3 expression in squamous cell carcinoma (SCC) was significantly higher than those in adenocarcinoma (p=0.048), while CD133 expression in large cell lung carcinoma was higher than that in SCC (p=0.023). The mean number of tumor-infiltrating lymphocytes (TILs) in the B7-H3-positive group was lower than that in the B7-H3-negative group (p=0.026). The mean TILs in the CD133-positive group was significantly lower than that in CD133-negative group (p=0.029). We found that CD133 was related to tumor cell differentiation degree and CD133 expression was negatively correlated with B7-H3 expression. The CD133 positive or B7-H3 negative was associated with poor prognosis of NSCLC patients by Cox regression analysis.
Both CD133 and B7-H3 might induce apoptosis of TILs in NSCLC and tumor evading host immune surveillance. Either CD133 or B7-H3 might be an independent risk factor of NSCLC participants.
检测B7-H3和CD133在人非小细胞肺癌（NSCLC）标本及肺良性病变中的表达，并评估这两种生物标志物与临床病理特征之间的相关性。
本研究为病例对照研究，收集了2006年1月至2008年12月期间在苏州大学附属第二医院接受胸外科手术的NSCLC患者的102份组织标本。在这102例患者中，25份相邻的非癌样本经病理证实为正常组织（阳性组），24份良性炎性病变组织作为对照（阴性组）。使用Image-Pro Plus软件对126例参与者的标本进行免疫组织化学染色，并在每个切片中测量细胞数量。
102份标本中，71份表达B7-H3，51份表达CD133，其表达水平高于良性病变（p<0.001）或非癌组织（p<0.001）。鳞状细胞癌（SCC）中B7-H3的表达明显高于腺癌（p=0.048），而大细胞肺癌中CD133的表达高于SCC（p=0.023）。B7-H3阳性组肿瘤浸润淋巴细胞（TILs）的平均数量低于B7-H3阴性组（p=0.026）。CD133阳性组的平均TILs明显低于CD133阴性组（p=0.029）。我们发现CD133与肿瘤细胞分化程度相关，且CD133表达与B7-H3表达呈负相关。通过Cox回归分析，CD133阳性或B7-H3阴性与NSCLC患者的预后不良相关。
CD133和B7-H3可能均诱导NSCLC中TILs的凋亡并导致肿瘤逃避宿主免疫监视。CD133或B7-H3可能是NSCLC患者的独立危险因素。
